Masakazu Takeuchi
Overview
Explore the profile of Masakazu Takeuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y
Lancet Diabetes Endocrinol
. 2022 Aug;
10(9):623-633.
PMID: 35914543
Background: As the disease progresses, many patients with type 2 diabetes have difficulty in reaching treatment goals. We aimed to assess the efficacy and safety of tirzepatide, a novel GIP...
12.
Onishi Y, Ishii H, Oura T, Takeuchi M
Diabetes Ther
. 2020 Jan;
11(3):735-745.
PMID: 31994009
Purpose: In East Asian patients, type 2 diabetes mellitus (T2DM) is characterized primarily by β-cell dysfunction, with lower insulin secretion than in Caucasian individuals. Therefore, bolus insulin and premixed insulin...
13.
Ishii H, Onishi Y, Oura T, Takeuchi M
Diabetes Ther
. 2019 Nov;
11(1):133-145.
PMID: 31758520
Introduction: Although global studies have investigated the combination of dulaglutide with insulin in patients with type 2 diabetes mellitus (T2DM), differences in lean body mass and dulaglutide dosing can complicate...
14.
Inoue M, Shiramoto M, Oura T, Nasu R, Nakano M, Takeuchi M
Diabetes Ther
. 2019 Apr;
10(3):1019-1027.
PMID: 30949907
Introduction: Dulaglutide is a recombinant glucagon-like peptide-1 immunoglobulin G4 Fc fusion protein approved for treating patients with type 2 diabetes (T2D). The aim of this study was to assess postprandial...
15.
Kaneko S, Oura T, Matsui A, Shingaki T, Takeuchi M
Endocr J
. 2017 Sep;
64(12):1165-1172.
PMID: 28904247
The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) compared with once-daily insulin glargine (glargine) in Japanese patients with type 2 diabetes were evaluated according to subgroups stratified by...
16.
Suzuki S, Oura T, Takeuchi M, Boye K
Health Qual Life Outcomes
. 2017 Jun;
15(1):123.
PMID: 28606095
Background: Standardized patient-reported outcome (PRO) questionnaires can be utilized to evaluate treatment satisfaction (subjective evaluation of treatment) in patients with type 2 diabetes (T2D). These outcomes are important because they...
17.
Hamano K, Nishiyama H, Matsui A, Sato M, Takeuchi M
Endocr J
. 2017 Mar;
64(4):449-456.
PMID: 28302958
In 855 Japanese patients with type 2 diabetes receiving once weekly dulaglutide 0.75 mg in 3 phase 3 studies, the effects on efficacy and safety at week 26 (last observation...
18.
Inagaki N, Araki E, Oura T, Matsui A, Takeuchi M, Tanizawa Y
Diabetes Obes Metab
. 2016 Aug;
18(12):1279-1282.
PMID: 27488246
The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents. This...
19.
Onishi Y, Oura T, Nishiyama H, Ohyama S, Takeuchi M, Iwamoto N
Endocr J
. 2015 Dec;
63(3):263-73.
PMID: 26698689
The efficacy and tolerability of once weekly dulaglutide 0.75 mg in Japanese patients with type 2 diabetes (T2D) were evaluated by subgroups defined by key demographic characteristics. This post hoc...
20.
Tamaki C, Takeuchi M, Iwamoto N, Glaesner W
Nihon Yakurigaku Zasshi
. 2015 Dec;
146(4):215-24.
PMID: 26656966
No abstract available.